SG10201710475WA - Preparing antibodies from cho cell cultures for conjugation - Google Patents
Preparing antibodies from cho cell cultures for conjugationInfo
- Publication number
- SG10201710475WA SG10201710475WA SG10201710475WA SG10201710475WA SG10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA SG 10201710475W A SG10201710475W A SG 10201710475WA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugation
- cell cultures
- cho cell
- preparing antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/03—Oxidoreductases acting on sulfur groups as donors (1.8) with oxygen as acceptor (1.8.3)
- C12Y108/03002—Thiol oxidase (1.8.3.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908568P | 2013-11-25 | 2013-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201710475WA true SG10201710475WA (en) | 2018-01-30 |
Family
ID=53180202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710475WA SG10201710475WA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
SG11201602995VA SG11201602995VA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602995VA SG11201602995VA (en) | 2013-11-25 | 2014-11-21 | Preparing antibodies from cho cell cultures for conjugation |
Country Status (14)
Country | Link |
---|---|
US (2) | US10457976B2 (ko) |
EP (1) | EP3074036B1 (ko) |
JP (2) | JP6529188B2 (ko) |
KR (1) | KR102306493B1 (ko) |
CN (1) | CN105979963B (ko) |
AU (1) | AU2014352824B2 (ko) |
CA (1) | CA2928238C (ko) |
DK (1) | DK3074036T3 (ko) |
EA (1) | EA034123B1 (ko) |
ES (1) | ES2753269T3 (ko) |
IL (1) | IL245190B (ko) |
MX (1) | MX2016006551A (ko) |
SG (2) | SG10201710475WA (ko) |
WO (1) | WO2015077605A1 (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150083689A (ko) * | 2014-01-10 | 2015-07-20 | 삼성전자주식회사 | 항 c-Met 항체 정제 방법 |
CN108064286A (zh) | 2015-01-26 | 2018-05-22 | 株式会社钟化 | 突变型免疫球蛋白κ链可变区结合性肽 |
JPWO2016121701A1 (ja) | 2015-01-26 | 2017-11-09 | 株式会社カネカ | 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス |
WO2017109619A1 (en) * | 2015-12-21 | 2017-06-29 | Pfizer Inc. | Purification of antibody drug conjugates using a sodium phosphate gradient |
WO2017195638A1 (ja) * | 2016-05-09 | 2017-11-16 | 株式会社カネカ | 抗体またはκ鎖可変領域含有抗体断片の精製方法 |
WO2018116269A1 (en) * | 2016-12-22 | 2018-06-28 | Lupin Limited | Depth filtration of a protein |
JP2022531317A (ja) * | 2019-05-03 | 2022-07-06 | ジェネンテック, インコーポレイテッド | 精製プラットフォームから得られた組成物中の酵素加水分解活性速度を低下させる方法 |
JP2022543273A (ja) | 2019-08-06 | 2022-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 生物医薬組成物及び関連する方法 |
WO2023012669A2 (en) | 2021-08-03 | 2023-02-09 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US8263750B2 (en) * | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
PL2840090T3 (pl) | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
KR101238061B1 (ko) | 2009-03-31 | 2013-02-27 | 한화케미칼 주식회사 | Vcam-1에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물 |
JP5870400B2 (ja) | 2010-04-15 | 2016-03-01 | シアトル ジェネティクス,インコーポレーテッド | 標的化ピロロベンゾジアゼピンコンジュゲート |
EP3483184A1 (en) | 2012-03-07 | 2019-05-15 | Yeda Research and Development Co. Ltd | Compositions for inhibition of quiescinsulfhydryl oxidase (qsox1) and uses of same |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
-
2014
- 2014-11-21 SG SG10201710475WA patent/SG10201710475WA/en unknown
- 2014-11-21 SG SG11201602995VA patent/SG11201602995VA/en unknown
- 2014-11-21 EA EA201691094A patent/EA034123B1/ru unknown
- 2014-11-21 DK DK14863650T patent/DK3074036T3/da active
- 2014-11-21 CA CA2928238A patent/CA2928238C/en active Active
- 2014-11-21 EP EP14863650.9A patent/EP3074036B1/en active Active
- 2014-11-21 WO PCT/US2014/066889 patent/WO2015077605A1/en active Application Filing
- 2014-11-21 CN CN201480064191.6A patent/CN105979963B/zh active Active
- 2014-11-21 ES ES14863650T patent/ES2753269T3/es active Active
- 2014-11-21 AU AU2014352824A patent/AU2014352824B2/en active Active
- 2014-11-21 MX MX2016006551A patent/MX2016006551A/es unknown
- 2014-11-21 KR KR1020167016632A patent/KR102306493B1/ko active IP Right Grant
- 2014-11-21 JP JP2016533645A patent/JP6529188B2/ja active Active
- 2014-11-21 US US15/039,179 patent/US10457976B2/en active Active
-
2016
- 2016-04-19 IL IL245190A patent/IL245190B/en active IP Right Grant
-
2018
- 2018-12-26 JP JP2018242033A patent/JP2019048888A/ja active Pending
-
2019
- 2019-09-17 US US16/573,154 patent/US20200063180A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2016006551A (es) | 2016-09-06 |
CN105979963B (zh) | 2020-03-03 |
JP2019048888A (ja) | 2019-03-28 |
EA201691094A1 (ru) | 2016-09-30 |
EP3074036B1 (en) | 2019-09-18 |
US10457976B2 (en) | 2019-10-29 |
US20170159099A1 (en) | 2017-06-08 |
EP3074036A4 (en) | 2017-07-26 |
IL245190B (en) | 2021-02-28 |
EP3074036A1 (en) | 2016-10-05 |
CA2928238C (en) | 2021-08-17 |
CN105979963A (zh) | 2016-09-28 |
WO2015077605A1 (en) | 2015-05-28 |
IL245190A0 (en) | 2016-06-30 |
CA2928238A1 (en) | 2015-05-28 |
JP2016539130A (ja) | 2016-12-15 |
AU2014352824B2 (en) | 2019-07-18 |
US20200063180A1 (en) | 2020-02-27 |
SG11201602995VA (en) | 2016-05-30 |
DK3074036T3 (da) | 2019-11-18 |
KR102306493B1 (ko) | 2021-09-28 |
JP6529188B2 (ja) | 2019-06-12 |
AU2014352824A1 (en) | 2016-05-12 |
EA034123B1 (ru) | 2019-12-30 |
ES2753269T3 (es) | 2020-04-07 |
KR20160089454A (ko) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264558A (en) | Anti–il–23p19 antibodies | |
IL271697A (en) | Antibodies against CXCR3 | |
HK1217023A1 (zh) | 新型抗體 | |
IL245190B (en) | Preparation of antibodies from cho cell cultures for conjugation | |
SG11201509441QA (en) | Method for producing sheet-shaped cell culture | |
HK1204571A1 (en) | Protease-regulated antibodies | |
IL235042A0 (en) | Anti–fcrn antibodies | |
EP2953892A4 (en) | PROCESSES FOR FUEL CONVERSION | |
IL236259A0 (en) | Anti 15–siglec antibodies | |
EP2895500A4 (en) | IMMUNOGENS INDUCING ANTIBODIES | |
HK1221250A1 (zh) | 用於培養細胞的結構件 | |
EP2970037A4 (en) | PROCESS FOR THE PREPARATION OF ALKYLFURANES | |
SG10201709290XA (en) | Anti-H7cr Antibodies | |
GB201420277D0 (en) | Cell culture system | |
PL2935330T3 (pl) | Przeciwciała przeciw notch3 | |
HK1202454A1 (en) | Anti-p-selectin antibody formulation -p- | |
GB201312226D0 (en) | Improved antibodies | |
EP2804876A4 (en) | NEW ANTIBODIES | |
EP2817395A4 (en) | PROCESS FOR THE PRODUCTION OF BIODIESEL | |
SG11201507338PA (en) | Method for culturing cells | |
GB201308905D0 (en) | Cell culture | |
GB201306488D0 (en) | Cell culture |